LEPU BIO-B (02157.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Oct30

NMPA Approves Leple Biotech's Injection of Vebetoclimab for Marketing

09:01

Oct17

Guotai Hexun First Covers Lepu Biopharma with an Overweight Rating

05:51

Oct16

Lepu Biopharma's 自主研发 MRG006A completes first patient enrollment in Phase II clinical trial for late-stage hepatocellular carcinoma

02:15

Aug20

LEPU BIO-B released FY2025 Q1 earnings on August 20 (BJT), actual revenue HKD 249.51 M, actual EPS HKD 0.0107

15:00

Chinese Innovative Pharma Companies First NewCo Transaction Led by Domestic Investors

12:36

LEPU BIO-B released FY2025 Q2 earnings on August 20 After-Market (BJT), actual revenue HKD 0, actual EPS HKD 0

11:00

Schedules & Filings

Schedules

Filings

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 254.99 M, Net Income 22.85 M, EPS 0.0109

Mar27

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 124.74 M, Net Income -116.46 M, EPS -0.068

Aug21

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 71.61 M, Net Income -103.39 M, EPS -0.0644

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change